PARP1 and cancer: As we discussed previously, PARP inhibitors have attracted intense interest because they can induce synthetic lethality in cancer cells harboring BRCA mutations, which is defined as “BRCAness”; defects in HR repair are mostly induced by BRCA1 or BRCA2 loss57.